medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 1

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (1)


Tropismo multifacético del SARS-CoV-2

Del Carpio-Orantes L, Sánchez-Díaz JS, García-Méndez S, Rosas-Lozano AL, Aguilar-Silva A, Mejía-Ramos SG

Idioma: Español
Referencias bibliográficas: 36
Paginas: 108-113
Archivo PDF: 229.50 Kb.


RESUMEN

El SARS-CoV-2 tiene predilección por los grupos celulares que son ricos en receptores ACE2 y TMPRSS2, los cuales están distribuidos a lo largo del cuerpo humano, lo que hace que, además del sitio primario de contagio o primoinfección, que es el aparato respiratorio, el virus tienda a diseminarse por diferentes mecanismos afectando prácticamente todos los órganos, aparatos y sistemas conocidos, con lo que su tropismo se hace extenso pudiendo condicionar cuadros diversos aunados al respiratorio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tyler KL. Pathogenesis | Animal viruses. Encyclopedia ofVirology 1999; 1175‐1184. doi:10.1006/rwvi.1999.0214.

  2. Del Carpio-Orantes L. Zika, ¿virus neurotrópico? [Zika, aneurotropic virus?]. Rev Med Inst Mex Seguro Soc 2016;54 (4): 540‐543.

  3. Del Carpio-Orantes L. Dengue for apparatus and systems.MEDtube Science 2015; Vol. III (3): 21-24.

  4. Li Yan-Chao, Bai Wan-Zhu, Hashikawa T. The neuroinvasivepotential of SARS-CoV2 May be at least partially responsiblefor the respiratory failure of COVID-19 patients. J Med Virol2020; 1-4. doi: 10.1002/jmv.25728.

  5. Sociedad Española de Neurología. Recomendaciones dela Sociedad Española de Neurología en relación con lapérdida de olfato como posible síntoma precoz de infecciónpor COVID-19. Madrid. Publicado el 21 de marzo de 2020.Consultado en versión electrónica.

  6. Mao L, Wang M, Chen S, He Q, et al. Neurological manifestationsof hospitalized patients with COVID-19 in Wuhan,China: a retrospective case series study. medRxiv 2020.doi: 10.1101/2020.02.22.20026500.

  7. Remes-Troche JM, Ramos-de-la-Medina A, Manríquez-Reyes M, Martínez-Pérez-Maldonado L, Lara EL, Solís-González MA. Initial gastrointestinal manifestations inpatients with SARS-CoV-2 in 112 patients from Veracruz(Southeastern Mexico). Gastroenterology 2020. doi:https://doi.org/10.1053/j.gastro.2020.05.055.

  8. Velarde-Ruiz Velasco JA, García-Jiménez ES, Remes-TrocheJM. Manifestaciones hepáticas y repercusion en el pacientecirrótico de covid-19 [Hepatic manifestations and impactof covid-19 on the cirrhotic patient.] [published onlineahead of print, 2020 May 27]. Rev Gastroenterol Mex 2020.doi:10.1016/j.rgmx.2020.05.002.

  9. Sultan S, Altayar O, Siddique SM, et al. AGA institute rapidreview of the GI and liver manifestations of COVID-19,meta-analysis of international data, and recommendationsfor the consultative management of patients withCOVID-19 [published online ahead of print, 2020 May5]. Gastroenterology 2020; S0016-5085 (20): 30593-X.doi:10.1053/j.gastro.2020.05.001.

  10. Puelles VG, Lütgehetmann M, Lindenmeyer MT, SperhakeJP, et al. Multiorgan and renal tropism of SARSCoV-2 [published online ahead of print, 2020 May13]. N Engl J Med 2020; NEJMc2011400. doi:10.1056/NEJMc2011400.

  11. Su H, Yang M, Wan C, Yi LX, et al. Renal histopathologicalanalysis of 26 postmortem findings of patients withCOVID-19 in China. Kidney Int 2020; 98 (1): 219-227. doi:10.1016/j.kint.2020.04.003.

  12. Centurión OA, Scavenius KE, García LB, Torales JM, MiñoLM. Potential mechanisms of cardiac injury and commonpathways of inflammation in patients with COVID-19[published online ahead of print, 2020 May 27]. CritPathw Cardiol 2020; 10.1097/HPC.0000000000000227.doi:10.1097/HPC.0000000000000227.

  13. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascularcomplications in COVID-19. Am J Emerg Med 2020; S0735-6757 (20): 30277-1. doi:10.1016/j.ajem.2020.04.048.

  14. Recalcati S. Cutaneous manifestations in COVID-19: a firstperspective. J Eur Acad Dermatol Venereol 2020; 34 (5):e212‐e213. doi:10.1111/jdv.16387.

  15. Galván-Casas C, Català A, Carretero-Hernández G,Rodríguez-Jiménez P, et al. Classification of the cutaneousmanifestations of COVID-19: a rapid prospective nationwideconsensus study in Spain with 375 cases. Br J Dermatol2020; 10.1111/bjd.19163. doi:10.1111/bjd.19163.

  16. Sánchez-Velázquez A, Falkenhain D, Rivera-Díaz R. Erythemamultiforme in the context of SARS-Coronavirus-2infection. Med Clin (Barc) 2020; S0025-7753 (20): 30267-0.doi:10.1016/j.medcli.2020.04.016.

  17. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associatedwith severe coronavirus disease 2019 (COVID-19)infections: A meta-analysis. Clin Chim Acta 2020; 506:145‐148. doi:10.1016/j.cca.2020.03.022.

  18. Tan L, Wang Q, Zhang D, et al. Correction: Lymphopeniapredicts disease severity of COVID-19: a descriptive andpredictive study. Signal Transduct Target Ther 2020; 5: 61.doi:10.1038/s41392-020-0159-1.

  19. Wang J, Saguner AM, An J, Ning Y, Yan Y, Li G. Dysfunctionalcoagulation in COVID-19: from cell to bedside. Adv Ther

  20. 2020; 10.1007/s12325-020-01399-7. doi:10.1007/s12325-020-01399-7.20. Bostanci Ceran B, Ozates S. Ocular manifestations of coronavirusdisease 2019. Graefes Arch Clin Exp Ophthalmol2020; 10.1007/s00417-020-04777-7. doi:10.1007/s00417-020-04777-7.

  21. Chen L, Deng C, Chen X, Zhang X, et al. Ocular manifestationsand clinical characteristics of 535 cases of COVID-19in Wuhan, China: a cross-sectional study. Acta Ophthalmol2020; 10.1111/aos.14472. doi:10.1111/aos.14472.

  22. Karimi S, Arabi A, Shahraki T, Safi S. Detection of severeacute respiratory syndrome Coronavirus-2 in the tears ofpatients with Coronavirus disease 2019. Eye (Lond) 2020;1‐4. doi:10.1038/s41433-020-0965-2.

  23. Ryean GA, Purandare NC, McAuliffe FM, Hod M, PurandareCN. Clinical update on COVID-19 in pregnancy: A reviewarticle. J Obstet Gynaecol Res 2020; 10.1111/jog.14321.doi:10.1111/jog.14321.

  24. Chen H, Guo J, Wang C, Luo F, et al. Clinical characteristicsand intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospectivereview of medical records. Lancet 2020; 395 (10226):809‐815. doi:10.1016/S0140-6736(20)30360-3.

  25. Liang H, Acharya G. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations tofollow? Acta Obstet Gynecol Scand 2020; 99 (4): 439‐442.doi:10.1111/aogs.13836.

  26. Harahsheh AS, Dahdah N, Newburger JW, Portman MA,Piram M, Tulloh R, et al. Missed or delayed diagnosisof Kawasaki disease during the 2019 novel coronavirusdisease (COVID-19) pandemic. J Pediatr. doi: 10.1016/j.jpeds.2020.04.052.

  27. Verdoni L, Mazza A, Gervasoni A, Martelli L, et al. Anoutbreak of severe Kawasaki-like disease at the Italianepicentre of the SARS-CoV-2 epidemic: an observationalcohort study. Lancet 2020; 10.1016/S0140-6736(20)31103-X. doi:10.1016/S0140-6736(20)31103-X.

  28. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N,Theocharis P. Hyperinflammatory shock in children duringCOVID-19 pandemic. Lancet 2020; 395 (10237): 1607‐1608.doi:10.1016/S0140-6736(20)31094-1.

  29. Alunno A, Carubbi F, Rodríguez-Carrio J. Storm, typhoon,cyclone or hurricane in patients with COVID-19?Beware of the same storm that has a different origin.RMD Open 2020; 6 (1): e001295. doi:10.1136/rmdopen-2020-001295.

  30. McGonagle D, Sharif K, O’Regan A, Bridgewood C. the roleof cytokines including interleukin-6 in COVID-19 inducedpneumonia and macrophage activation syndrome-like disease.Autoimmun Rev 2020; 19 (6): 102537. doi:10.1016/j.autrev.2020.102537

  31. Speer G, Somogyi P. Thyroid complications of SARS andcoronavirus disease 2019 (COVID-19). Endocr J 2021; 68(2): 129-136. doi: 10.1507/endocrj.EJ20-0443.

  32. Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids,and adrenal insufficiency. Biomed Pap Med FacUniv Palacky Olomouc Czech Repub 2021; 165 (1): 1-7.doi: 10.5507/bp.2021.011.

  33. Alzahrani AS, Mukhtar N, Aljomaiah A, Aljamei H, BakhshA, Alsudani N, Elsayed T, Alrashidi N, Fadel R, AlqahtaniE, Raef H, Butt MI, Sulaiman O. The impact of COVID-19viral infection on the hypothalamic-pituitary-adrenalaxis. Endocr Pract 2021; 27 (2): 83-89. doi: 10.1016/j.eprac.2020.10.014.

  34. Selek A, Güçlü M, Bolu ŞE. COVID-19 pandemic: whatabout the gonads? Hormones 2021; 20 (2): 259-268. doi:10.1007/s42000-021-00277-3.

  35. Abramczyk U, Nowaczyński M, Słomczyński A, WojniczP, Zatyka P, Kuzan A. Consequences of COVID-19 for thepancreas. Int J Mol Sci 2022; 23 (2): 864. doi: 10.3390/ijms23020864.

  36. Del Carpio-Orantes L. Zika and novel coronavirus 2019(2019-nCoV): Pandemic viruses sharing similarities. ArchClin Infect Dis 2020; 15 (3): e103011.




2020     |     www.medigraphic.com